Rigel Pharmaceuticals Inc. has appointed Michael P. Miller to its board of directors, effective February 1, 2026. As part of his compensation, Mr. Miller will receive a yearly retainer of $50,000 and an additional $10,000 annually for his service on the Compensation Committee, both pro-rated for any partial service period. He was also granted an initial stock option to purchase 12,000 shares under the company’s 2018 Equity Incentive Plan. Following each annual meeting of stockholders, Miller will automatically receive an annual option for 3,000 shares and 2,500 restricted stock units, pro-rated for partial years, as long as he continues to serve as a non-employee board member.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001034842-26-000007), on February 03, 2026, and is solely responsible for the information contained therein.